Characterization of Human Cytochrome P450 Enzymes Involved in the Metabolism of Cilostazol

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Drug Metabolism And Disposition

• Publication date

  2007-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.107.016758PMID 17646278
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CYP3A5 GENETIC POLYMORPHISMS IN DIFFERENT ETHNIC POPULATIONS

  2005cited by this paper
• Genetic variability in CYP3A5 and its possible consequences.

  2004cited by this paper
• Cilostazol

  2002cited by this paper
• Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population

  2002cited by this paper
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001cited by this paper
• Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography.

  2001cited by this paper
• In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms

  2000influential reference
• Effects of CYP3A Inhibition on the Metabolism of Cilostazol

  1999cited by this paper
• Cilostazol Pharmacokinetics after Single and Multiple Oral Doses in Healthy Males and Patients with Intermittent Claudication Resulting from Peripheral Arterial Disease

  1999influential reference
• Effect of Omeprazole on the Metabolism of Cilostazol

  1999cited by this paper
• Achieving an Optimal Outcome in the Treatment of Infections

  1999cited by this paper
• Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.

  1998cited by this paper
• Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.

  1998cited by this paper
• Impact of cilostazol on intimal proliferation after directional coronary atherectomy.

  1998cited by this paper
• Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects

  1996cited by this paper
• Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

  1994cited by this paper
• The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

  1994cited by this paper
• The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man.

  1985cited by this paper

• In Vitro/In Vivo Correlation of Two Extended-Release Cilostazol Formulations

  2024cites this paper
• Cilostazol versus Aspirin or Clopidogrel for Reducing Post-Stroke Aspiration Pneumonia: A Nationwide Retrospective Cohort Study

  2023cites this paper
• Genotype-guided dual antiplatelet therapy in cerebrovascular disease: assessing the risk and benefits for ethnic populations

  2023cites this paper
• Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases.

  2023cites this paper
• Prevalence and associated factors of severe proton pump inhibitors drug interactions in community pharmacy: a network analysis approach.

  2023cites this paper
• Effect of Baicalein on the Pharmacokinetics of Cilostazol and Its Two Metabolites in Rat Plasma Using UPLC-MS/MS Method

  2022cites this paper
• Cilostazol for Secondary Stroke Prevention

  2021cites this paper
• A new simple method for quantification cilostazol and its active metabolite in human plasma by LC-MS/MS: Application to pharmacokinetics of cilostazol associated with CYP genotypes in healthy Chinese population.

  2021cites this paper
• Impact of Cilostazol Pharmacokinetics on the Development of Cardiovascular Side Effects in Patients with Cerebral Infarction.

  2021cites this paper
• A simple LC-MS/MS method for simultaneous determination of cilostazol and ambroxol in Sprague-Dawley rat plasma and its application to drug-drug pharmacokinetic interaction study following oral delivery in rats.

  2021cites this paper
• Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template.

  2020cites this paper
• Drug discovery with explainable artificial intelligence

  2020cites this paper
• Antiplatelet drugs overview

  2020cites this paper
• 3D-Quantitative Structure Metabolism Relationship (QSMR) Studies of CYP3A4 Substrates

  2019cites this paper
• Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction.

  2018cites this paper
• Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites

  2018cites this paper
• Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy

  2018cites this paper
• Cilostazol for treatment of cerebral infarction

  2018cites this paper
• Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans.

  2017cites this paper
• Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

  2016influential citation
• Local Drug–Drug Interaction of Donepezil with Cilostazol at Breast Cancer Resistance Protein (ABCG2) Increases Drug Accumulation in Heart

  2016influential citation
• The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.

  2016cites this paper
• Pharmacokinetic comparison of sustained- and immediate-release formulations of cilostazol after multiple oral doses in fed healthy male Korean volunteers

  2015cites this paper
• Blood Brain Barrier Dysfunction in Chronic Cerebral Ischemia

  2015cites this paper
• Population Pharmacokinetic Analysis of Diurnal and Seasonal Variations of Plasma Concentrations of Cilostazol in Healthy Volunteers

  2014cites this paper
• Cilostazol eliminates adverse smoking outcome in patients with drug-eluting stent implantation.

  2014cites this paper
• Determination of cilostazol and its active metabolite 3,4-dehydro cilostazol from small plasma volume by UPLC−MS/MS

  2014cites this paper
• Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study.

  2014cites this paper
• The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects.

  2014cites this paper
• Design and applications of bioprecursors: a retrometabolic approach.

  2014cites this paper
• Pharmacological inhibition of platelet reactivity. Clinical and pharmacodynamic effects.

  2013cites this paper
• Effect of phenytoin on the pharmacokinetics of efavirenz in rabbits

  2012cites this paper
• Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.

  2012cites this paper
• Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss‐of‐function allele (ACCEL‐SWITCH) study

  2012cites this paper
• Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition.

  2012cites this paper
• Optimization of the Bacterial Cytochrome P450 BM3 System for the Production of Human Drug Metabolites

  2012cites this paper
• Predicting oxidation sites with order of occurrence among multiple sites for CYP4A-mediated reactions.

  2011cites this paper
• Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period

  2011cites this paper
• The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.

  2011cites this paper
• Cilostazol to overcome high on-treatment platelet reactivity in korean patients treated with clopidogrel and calcium-channel blocker.

  2011cites this paper
• Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-.

  2011cites this paper
• Cilostazol in patients with ischemic stroke

  2011influential citation
• Sex differences in pharmacokinetics of cilostazol in rats

  2011cites this paper
• Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.

  2011cites this paper
• Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants.

  2010cites this paper
• Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.

  2010cites this paper
• Cytochrome 2 C 19 Polymorphism and Response to Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention

  2010cites this paper
• Comparison of the Contributions of Cytochromes P450 3A4 and 3A5 in Drug Oxidation Rates and Substrate Inhibition

  2010influential citation
• Adding Cilostazol to Dual Antiplatelet Therapy Achieves Greater Platelet Inhibition than High Maintenance Dose Clopidogrel in Patients With Acute Myocardial Infarction: Results of the Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With AMI (ACCEL-AMI) Study

  2010cites this paper
• Cytochrome 2C19 Polymorphism and Response to Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention

  2010cites this paper
• Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).

  2010cites this paper
• Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.

  2010cites this paper
• Negligible Effect of Ginkgo Biloba Extract on the Pharmacokinetics of Cilostazol

  2009cites this paper
• Influence of CYP3A and CYP2C19 Genetic Polymorphisms on the Pharmacokinetics of Cilostazol in Healthy Subjects

  2009cites this paper
• The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post‐treatment platelet reactivity in Asian patients with acute coronary syndrome

  2009cites this paper
• Role of cytochrome P450 in drug interactions

  2008cites this paper